Skip to main content

Rosetta Genomics to Collaborate with Columbia U. on Lymphoma Biomarkers

NEW YORK (GenomeWeb News) - Rosetta Genomics will collaborate with Columbia University to develop microRNA-based diagnostic tests for early detection and prognosis of certain types of non-Hodgkin lymphoma and leukemia, Rosetta said today.
 
Under the collaboration, Rosetta Genomics and Columbia researchers will screen for microRNAs that could serve as biomarkers and drug targets for diffuse large cell lymphoma, transformed follicular lymphoma, and chronic lymphocytic leukemia.
 
According to Rosetta Genomics Head of Global R&D Dalia Cohen, 40 percent of DLCL patients respond well to current therapies and have prolonged survival, but researchers do not know why the remainder of patients don’t respond to therapy. "We believe our technology will help answer this question, as well as speed up and simplify the diagnostic process,” Cohen said.
 
The American Cancer Society estimates that around 43,000 people in the US will be diagnosed with these cancers in 2007.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.